Related Experiment Videos
[Monoclonal antibodies in diagnosis and therapy]
1Urologische Klinik, FU Berlin, Klinikum Steglitz.
Immunitat Und Infektion
|February 1, 1989
Abstract:
The value of monoclonal antibodies (mAb) produced against renal, bladder and prostate cancer antigens is demonstrated. These mAb allow a molecular classification of urological cancers as well as therapeutic approaches in cancer treatment. Anti-T-cell mAb can also be used in cellular rejection of kidney transplants.
Insights
Monoclonal antibodies (mAbs) targeting cancer antigens offer molecular classification and new therapies for kidney, bladder, and prostate cancers. These antibodies also play a role in preventing kidney transplant rejection.
Area of Science:
- Oncology
- Immunology
- Urology
Context:
- Monoclonal antibodies (mAbs) are increasingly vital in understanding and treating various cancers.
- Urological cancers, including renal, bladder, and prostate cancers, present unique challenges in diagnosis and therapy.
- The role of immune responses in solid tumors and organ transplantation is a critical area of research.
Purpose:
- To demonstrate the utility of monoclonal antibodies (mAbs) against specific antigens in urological cancers.
- To highlight the potential of mAbs for molecular subtyping of renal, bladder, and prostate tumors.
- To explore the application of anti-T-cell mAbs in managing kidney transplant rejection.
Summary:
- Monoclonal antibodies (mAbs) targeting renal, bladder, and prostate cancer antigens facilitate molecular classification of these malignancies.
- Therapeutic strategies leveraging these specific mAbs are advancing cancer treatment paradigms.
- Additionally, anti-T-cell mAbs show promise in mitigating cellular rejection following kidney transplantation.
Impact:
- Establishes mAbs as key tools for precise urological cancer classification and targeted therapy development.
- Opens avenues for novel immunotherapeutic approaches in urological oncology.
- Provides a basis for improved management of immune-related complications in kidney transplantation.